New projections in the Lancet forecast an alarming prevalence of diabetes by 2050

A new analysis done as part of the 2021 Global Burden of Disease Study tells a harrowing tale about a disease that is already one of the leading causes of death and disability worldwide. The global burden of diabetes is expected to increase in the coming decades—particularly Type II diabetes. While there are many exciting innovations coming out of our industry for treating and managing this disease, medtech hasn’t quite found its footing in diabetes prevention. These findings should be our industry’s call to action on this front—especially to imagine solutions beyond GLP-1s.